Ribo Included in HSCI, Set to Become Stock Connect Southbound Eligible Investment Target
August 21, 2026 · Hong Kong, China
Suzhou Ribo Life Science Co., Ltd. (Ribo, 06938.HK) is pleased to announce the Company's stock is included in the Hang Seng Composite Index (HSCI) according to the Hang Seng Indexes Company's semi-annual review for the period ending June 30, 2026. The adjustment will be implemented after market closes on September 4 (Friday), 2026, and will take effect from September 7(Monday), 2026.
Following its inclusion in the HSCI, Ribo's shares are expected to concurrently become eligible for trading under the Hong Kong Stock Connect, providing mainland Chinese investors with a more convenient trading channel, which will further broaden Ribo's shareholder base, improve share trading liquidity and market profile, and facilitate engagement with a greater pool of high-quality institutional investors both in mainland China and overseas.
Dr. Liang Zicai, Chairman and CEO of Ribo, commented: "The inclusion of Ribo in the HSCI represents a significant milestone in our development journey. It fully affirms the capital market's comprehensive recognition of our siRNA innovation technology platform, differentiated product pipeline, global R&D capabilities and business footprint. It also marks Ribo's entry into a new phase featuring two-way connectivity between domestic and international capital markets. The inclusion in HSCI, coupled with concurrent eligibility for the Stock Connect Scheme will provide domestic and international investors with a more convenient portfolio allocation channel, further broaden our shareholder base and improve share liquidity, and deliver greater capital support to fuel Ribo’s sustained long-term development."
About the Hang Seng Composite Index (HSCI)
The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about the top 95% of the total market capitalization of companies listed on the Main Board of the Stock Exchange of Hong Kong. Adopting the freefloat-adjusted market capitalization methodology, the HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks. It is one of the most critical benchmark indices in Hong Kong's capital market.
For further details, please refer to the relevant announcements (http://www.hsi.com.hk/static/uploads/contents/en/news/pressRelease/20260821T174500.pdf) published on the website of Hang Seng Indexes Company Limited (http://www.hsi.com.hk).
About Ribo
Suzhou Ribo Life Science Co., Ltd. (Ribo, 06938.HK) is a global biopharmaceutical company dedicated to the development and commercialization of small interfering RNA (siRNA) therapeutics. Leveraging its self-developed siRNA technology platform, Ribo has established a comprehensive and differentiated product pipeline targeting major disease areas such as cardiovascular metabolism, liver, and kidney disorders. Ribo is committed to delivering revolutionary treatment solutions to patients worldwide through continuous innovation. For more information, visit: www.ribolia.com.